Five abstracts were selected for 2022 AACR.
These wall posters will introduce the progress of the company's early clinical and preclinical pipeline.
The types of pipelines involved include ATG-037, ATG-018, ATG-022, ATG-012 and ATG-008.
March 9, 2022 / PRNewswire /-- leading innovative biopharmaceutical company Deqi Pharmaceutical Co., Ltd. ("Deqi Pharmaceuticals", HKEx: 6996.HK), a leading commercial innovative biopharmaceutical company dedicated to R & D, production and sale of the first and / or best-of-its-kind blood and solid tumor therapy.The company willFive summary wall posters were presented at the 2022 American Association of Cancer Research (AACR 2022) Annual meeting, both offline and online, in New Orleans, April 8-13.
Dr. Shan Bo, Chief Scientific Officer of Deqi PharmaceuticalThe preclinical study we will present at AACR 2022 will provide outsiders with information on the targets of the five pipeline varieties, as well as in vivo and in vitro research data to support further clinical development. These research data play an important guiding role in the formulation of our clinical development program. at the same time, it also reveals some potential combination therapy and some new biomarkers and genetic mutations that can be used to predict efficacy and improve the response rate of treatment. We are pleased to have the opportunity to share this data with our counterparts in the field of oncology. "
The following is the details of the summary wall newspaper:
Title:ATG-037, a potent small molecule inhibitor of CD73, can reverse immunosuppression in high AMP microenvironment more effectively than anti-CD73 antibody drugs.
Summary number:2576
Sub-venue:Cell cycle, proliferation inhibitors and immunotherapeutic drugs
Date and time:9:00 to 12:30 on April 12, 2022 (US Central time)
Location:Wall poster display area 21
The purpose of this study is to compare the efficacy and selectivity of oral administration.Anti-tumor activity of CD73 small molecule inhibitor ATG-037 and two anti-CD73 antibody drugs.CD73 is an enzyme highly expressed in tumor microenvironment, which can degrade AMP into adenosine, which leads to immunosuppression and tumor deterioration. Through experiments, the study evaluated the ability of each drug to inhibit CD73 and reverse AMP/adenosine-mediated T cell inhibition. Compared with the other two antibodies, ATG-037 showed stronger activity and could completely inhibit the activity of CD73 on the cell surface. In addition, the authors concluded that ATG-037 can restore T cell function more effectively in high AMP environment than other anti-CD73 antibody drugs that have been used in clinic. These data show that small molecular inhibitors have potential therapeutic advantages over blocking antibodies.Deqi Medicine is working on a projectPhase I clinical trial of ATG-037 monotherapy and combined anti-PD-1 antibodies in patients with advanced / metastatic solid tumors.
Title:Efficacy of a novel ATR inhibitor ATG-018 in preclinical tumor model
Summary number:2604
Sub-venue:DNA damage response and repair
Date and time:9:00 to 12:30 on April 12, 2022 (US Central time)
Location:Wall poster display area 22
The preclinical study reviewed supportData developed by ATG-018, a small molecule inhibitor of ATR.ATR kinases (ataxic telangiectasia and Rad3--associated kinases) play a certain role in DNA injury response (DDR). The study evaluated the anti-proliferative activity of ATG-018 in a group of 143tumor cell lines and 3 CDX mouse models and identified potential predictive biomarkers. ATG-018 showed a strong inhibition on the proliferation of cancer cells, and did not affect the survival of normal peripheral blood monocytes. In the CDX model, ATG-018 showed dose-dependent inhibition of tumor growth. In conclusion, the authors point out that ATG-018 has shown monotherapy efficacy in multiple solid / hematological tumors with lack of homologous recombination in vivo and in vitro. In addition, a number of genetic variants related to ATG-018 sensitivity have been found, which have the potential to become predictive biomarkers.These data show that there is a lack of homologous reorganization.In patients with gene mutation, ATG-018 may be a potential drug for treatment.
Title:The antibody-coupled drug ATG-022 targeting Claudin 18.2 showed excellent in vivo efficacy in gastric cancer patients with xenotransplantation.
Summary number:1143
Sub-venue:Preclinical and clinical pharmacology
Date and time:11 April 2022 9:00 to 12:30 (US Central time)
Location:Wall poster display area 25
This preclinical study targeted multiple xenotransplantation models in patients with gastric cancer.The antibody-coupled drug ATG-022 of Claudin 18.2 (CLDN18.2) was evaluated to determine its therapeutic potential at different levels of CLDN18.2 expression.CLDN18.2 is overexpressed in a considerable number of gastric and pancreatic cancers. Studies of monoclonal antibody drugs (IMAB362) against CLDN18.2 have shown that although the drug combined with chemotherapy shows positive clinical benefits, it is not effective in patients with low expression of CLDN18.2. The preclinical study, to be presented at the AACR conference, shows that ATG-022 binds to CLDN18.2 with a very high affinity (below the nanomole level) and shows strong anti-tumor activity in vivo and in vitro. In addition, this study also observed significant in vivo efficacy in tumor models with low expression of CLDN18.2. In conclusion, the authors point out that ATG-022 shows the potential to bring clinical benefits to gastric cancer patients with different levels of CLDN18.2 expression.At present, Deqi Medicine is advancing.Preclinical study of ATG-022.
Title:Synergistic effect of Kras (G12C) inhibitors combined with SHP2, ERK1/2, mTORC1/2 or XPO1 inhibitors in tumors carrying Kras (G12C) mutations
Summary number:2679
Sub-venue:Signal pathway inhibitor
Date and time:9:00 to 12:30 on April 12, 2022 (US Central time)
Location:Wall poster display area 25
The preclinical study aims to find a way to overcomeKRAS G12C inhibitor therapy is a common clinical dilemma of short progression-free survival.In this study, the antitumor activity of KRAS G12C inhibitor ATG-012 in combination with four drugs of multiple tumor pathways was evaluated in a solid tumor CDX model. These drugs are: 1) SHP2 inhibitors, ET0038;2) ERK 1 TORC1/2 kinase inhibitors, ATG-017;3) TORC1/2 kinase inhibitors, ATG-008;4) XPO-1 inhibitors, Serinesol. Not only ATG-012 alone can significantly inhibit tumor growth, the authors also pointed out that the combination of these four drugs and ATG-012 showed obvious synergistic effect in vivo throughout the study.These data reveal a number of potentialATG-012 combined therapy can be further clinically verified in tumor patients with KRAS G12C mutation in the future.
Title:MUC5B mutation can be used as a biomarker to predict the efficacy of mTORC1/2 inhibitor ATG-008 in the treatment of lung cancer.
Summary number:4032
Sub-venue:Molecular pharmacology
Date and time:April 13, 2022 9:00 to 12:30 (US Central time)
Location:Wall poster display area 26
The study aims to find outMTORC1/2 inhibitor ATG-008 (Onatasertib) is a predictive biomarker in the treatment of lung cancer.This study shows that MUC5B mutation is positively correlated with the efficacy of ATG-008, which can potentially improve the response rate of lung cancer patients to the drug. ATG-008 is a dual kinase inhibitor of mTOR complex 1 and 2. MTOR complex has a regulatory effect on cell growth, metabolism, proliferation and survival. Although there is usually a down-regulation of mTOR pathway in tumors, the efficacy of mTOR inhibitors in the treatment of lung cancer is limited. Thirty-one lung cancer cell lines in the study were treated with ATG-008 to determine the dose response and to find the gene mutations, amplification and expression associated with ATG-008 sensitivity, and the results were verified in mouse CDX lung cancer models with and without MUC5B mutations. ATG-008 showed more potent inhibition of tumor growth than the wild type model in the mouse CDX model with MUC5B mutation. In conclusion, the authors point out that MUC5B mutation is related to the stronger anti-tumor activity of ATG-008 in lung cancer mouse model. These data provide support for clinical trials of ATG-008.At present, Deqi Medicine is in the process ofATG-008 was evaluated in phase I and II clinical trials.
About Deqi Medicine
Deqi Pharmaceutical Co., Ltd. ("Deqi Pharmaceuticals", HKEx: 6996.HK) is a leading R & D-driven and commercialized biopharmaceutical company dedicated to providing leading treatments for patients in the Asia-Pacific region and around the world to treat tumors and other life-threatening diseases. Since its official operation in 2017, Deqi Pharmaceutical has established a rich product pipeline from preclinical to clinical stage through cooperative introduction and independent research and development. At present, Deqi Pharmaceutical has 15 products under research, 5 of which have Asia-Pacific interests, including the Greater China market, and 10 products have global interests. Deqi Pharmaceutical has obtained 22 clinical approvals (IND) in the United States and several Asia-Pacific markets and submitted 6 new drug marketing applications (NDA), of which Serineso / ATG-010/XPOVIO ®has been approved by new drug marketing applications in China, South Korea, Singapore and Australia. Deqi Medicine will use "Doctors are boundless and innovation is sustainable."for the vision, focus on the early development, clinical research, drug production and commercialization of the first and best treatments of the same kind, to address the clinical needs that need to be met urgently.